Atidarsagene Autotemcel PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Autologous CD34+ cells are transduced ex vivo with a lentiviral vector encoding functional human arylsulfatase A (ARSA), then reinfused after conditioning. Transduced cells engraft and provide ARSA-expressing progeny, including myeloid-lineage cells, to restore enzyme activity and reduce sulfatide accumulation in the nervous system.
Indications / reported uses
Treatment of selected presymptomatic late-infantile or early-juvenile and early-symptomatic early-juvenile metachromatic leukodystrophy (MLD) caused by biallelic ARSA mutations and deficient ARSA activity; eligibility depends on clinical stage and preserved function under the applicable product label
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Atidarsagene Autotemcel PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Atidarsagene Autotemcel Permitted Daily Exposure (PDE) report (the Atidarsagene Autotemcel PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Atidarsagene Autotemcel Occupational Exposure Limit (OEL) report (the Atidarsagene Autotemcel OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.